Black Diamond Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income $9.0 million.
“Net loss for the first quarter of 2026 was $9.0 million, as compared to net income of $56.5 million for the same period in 2025.”
Black Diamond Therapeutics, Inc. — fact timeline
Source-grounded facts extracted from Black Diamond Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Black Diamond Therapeutics, Inc. reported the year ended December 31, 2025 results: net income Net income for the year ended December 31, 2025 was $22.4 million compared to a net loss of $69.7 million for the year e.
“Net income for the year ended December 31, 2025 was $22.4 million compared to a net loss of $69.7 million for the year ended December 31, 2024.”
Black Diamond Therapeutics, Inc. reported the fourth quarter of 2025 results: net income Net loss for the fourth quarter of 2025 was $15.1 million.
“Net loss for the fourth quarter of 2025 was $15.1 million, as compared to $16.0 million for the same period in 2024.”
Erika Jones was appointed as principal financial officer at Black Diamond Therapeutics, Inc..
“Erika Jones, the Company’s Senior Vice President, Finance and Corporate Controller, and principal accounting officer, was appointed as principal financial officer of the Company.”
Fang Ni was terminated as Chief Business Officer, Chief Financial Officer and principal financial officer at Black Diamond Therapeutics, Inc..
“On October 7, 2024, Black Diamond Therapeutics, Inc. (the “Company”) terminated Fang Ni, Pharm. D. without Cause (as such term is defined in his employment agreement with the Company, which was filed as Exhibit 10.12 to the Company’s Annual Report on Form 10-K filed on March 9, 2023 (the “Employment Agreement”)) as Chief Business Officer, Chief Financial Officer and principal financial officer of the Company, in each case, effective as of October 7, 2024”
Black Diamond Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income $18.2 million.
“Net loss for the first quarter of 2024 was $18.2 million”
Prakash Raman was appointed as Director at Black Diamond Therapeutics, Inc..
“the Board appointed (i) Prakash Raman, Ph.D. to serve on the Board as a Class I director”
Wendy L. Dixon resigned as Director at Black Diamond Therapeutics, Inc..
“Wendy L. Dixon, Ph.D. resigned from the Board and all committees thereof, including her position as Chair of the Nominating and Corporate Governance Committee of the Board”
Alexander Mayweg resigned as Director at Black Diamond Therapeutics, Inc..
“Alexander Mayweg, Ph.D. resigned from the Board of Directors (the “Board”) of Black Diamond Therapeutics, Inc. (the “Company”).”
Black Diamond Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023 was $82.4 million.
“Net loss for the year ended December 31, 2023 was $82.4 million compared to $91.2 million for the year ended December 31, 2022.”
Black Diamond Therapeutics, Inc. reported the fourth quarter ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $19.4 million.
“Net loss for the fourth quarter of 2023 was $19.4 million, as compared to $21.1 million for the same period in 2022.”
Rajeev Shah resigned as Director at Black Diamond Therapeutics, Inc..
“Rajeev Shah notified Black Diamond Therapeutics, Inc. (the “Company”) of his intent to resign from the Company’s Board of Directors (the “Board”), including his position as a member of the Audit Committee of the Board, effective immediately.”
Black Diamond Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.
“On November 6, 2023, Black Diamond Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2023.”
Samarth Kulkarni was appointed as Lead Independent Director at Black Diamond Therapeutics, Inc..
“The Board appointed Samarth Kulkarni, Ph.D. to serve as the Lead Independent Director of the Board”
Mark A. Velleca was appointed as President and Chief Executive Officer at Black Diamond Therapeutics, Inc..
“Effective September 16, 2023, the Board appointed Mark A. Velleca, M.D., Ph.D. as President and Chief Executive Officer and principal executive officer of the Company”
David M. Epstein departed as President and Chief Executive Officer at Black Diamond Therapeutics, Inc..
“On September 18, 2023, Black Diamond Therapeutics, Inc. (the “Company”) announced that it separated with David M. Epstein, Ph.D. as President and Chief Executive Officer and principal executive officer of the Company, in each case, effective as of September 15, 2023”
Black Diamond Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.
“Black Diamond Therapeutics, Inc. announced its financial results for the second quarter ended June 30, 2023.”
Black Diamond Therapeutics, Inc. entered into Underwriting Agreement with Piper Sandler & Co., as representative of the several underwriters valued at approximately $71.6 million (effective 2023-06-29).
“On June 29, 2023, Black Diamond Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co., as representative of the several underwriters named in Schedule 1 thereto (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell up to 15,000,000 shares (the “Shares”) of common stock”
Black Diamond Therapeutics, Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2023 at the 2023-05-16 meeting.
“Proposal No. 2 The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. The results of the ratification were as follows: FOR AGAINST ABSTAIN 31,012,770 22,331 17,856”
Black Diamond Therapeutics, Inc. shareholders approved Election of three Class III director nominees at the 2023-05-16 meeting.
“Proposal No. 1 David M. Epstein, Wendy L. Dixon and Kapil Dhingra were duly elected to the Board as Class III directors. The results of the election were as follows: CLASS II DIRECTOR NOMINEE FOR WITHHELD BROKER NON- VOTES David M. Epstein 26,357,348 84,077 4,611,532 Wendy L. Dixon 19,131,310 7,310,115 4,611,532 Kapil Dhingra 20,012,773 6,428,652 4,611,532”
Black Diamond Therapeutics, Inc. reported financial results for first quarter ended March 31, 2023.
“Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.”
Black Diamond Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.
“On March 9, 2023, Black Diamond Therapeutics, Inc. announced its financial results for the year and three months ended December 31, 2022.”
Mark A. Velleca was appointed as Chairman of the Board at Black Diamond Therapeutics, Inc..
“On December 15, 2022, upon the recommendation of the NCG Committee, the Board appointed current Board member Mark A. Velleca, M.D., Ph.D. to serve as Chairman of the Board.”
Robert A. Ingram resigned as Chairman of the Board at Black Diamond Therapeutics, Inc..
“On December 13, 2022, Robert A. Ingram notified Black Diamond Therapeutics, Inc. (the “Company”) of his intent to resign from the Company’s Board of Directors (the “Board”), including his position of Chairman of the Board”
Black Diamond Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.
“Black Diamond Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2022.”
Wendy L. Dixon was appointed as Class III Director at Black Diamond Therapeutics, Inc..
“On April 6, 2022 (the “Effective Date”), upon the recommendation of its Compensation, Nomination and Corporate Governance Committee, the Board appointed Wendy L. Dixon, Ph.D. to serve on the Board as a Class III director”
Brad Bolzon resigned as Director at Black Diamond Therapeutics, Inc..
“On April 5, 2022, Brad Bolzon, Ph.D. notified Black Diamond Therapeutics, Inc. (the “Company”) of his intent to resign from the Company’s Board of Directors (the “Board”), effective immediately.”
Erika Jones was appointed as principal accounting officer at Black Diamond Therapeutics, Inc..
“Effective November 19, 2021, the Board appointed Erika Jones, the Company’s Vice President, Finance and Corporate Controller, as principal accounting officer until a successor is appointed.”
Fang Ni was appointed as Interim Chief Financial Officer at Black Diamond Therapeutics, Inc..
“Effective November 19, 2021, the Board of Directors of the Company (the “ Board ”) appointed Fang Ni, Pharm. D., the Company’s Chief Business Officer, as Interim Chief Financial Officer and principal financial officer until a successor is appointed.”
Thomas Leggett resigned as Chief Financial Officer at Black Diamond Therapeutics, Inc..
“On November 16, 2021, Thomas Leggett resigned from his position as Chief Financial Officer (principal financial and accounting officer) of Black Diamond Therapeutics, Inc. (the “ Company ”) effective immediately.”
Mark Velleca was appointed as Class I Director at Black Diamond Therapeutics, Inc..
“appointed Mark Velleca, M.D., Ph.D. to serve on the Board as a Class I director”
Christopher Roberts resigned as Chief Scientific Officer at Black Diamond Therapeutics, Inc..
“Dr. Buck succeeds Christopher Roberts, Ph.D., Chief Scientific Officer, who notified the Company on July 12, 2021 of his resignation from the Company to assume the role of chief executive officer at another company.”
Elizabeth Buck was appointed as Chief Scientific Officer at Black Diamond Therapeutics, Inc..
“Effective August 11 , 2021, Dr. Buck succeeds Christopher Roberts, Ph.D., Chief Scientific Officer, who notified the Company on July 12, 2021 of his resignation from the Company to assume the role of chief executive officer at another company.”
Rachel Humphrey departed as Chief Medical Officer at Black Diamond Therapeutics, Inc..
“Dr. Witt succeeds Rachel Humphrey, M.D., Chief Medical Officer, effective August 4, 2021.”
Karsten Witt was appointed as Interim Chief Medical Officer at Black Diamond Therapeutics, Inc..
“Dr. Witt succeeds Rachel Humphrey, M.D., Chief Medical Officer, effective August 4, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.